Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

BeiGene & Guangzhou Development District to set up $ 330 mn biologics plant

JV will also provide funding for research and development of biologic drug candidates in China

BS B2B Bureau  |  Beijing, China 

BeiGene & Guangzhou Development District to set up $ 330 mn biologics plant

Chinese biotechnology company Ltd and (GDD) have formed a joint venture, Co Ltd, that will invest RMB 2.2 billion ($ 330 million) to build a manufacturing facility in Guangzhou, Guangdong Province, China. The joint venture will also provide funding for research and development of biologic drug candidates in China.

“We are very pleased to announce our joint venture with the represent an important part of BeiGene’s overall R&D and manufacturing capabilities. This joint venture will enable to keep pace with a growing demand for the development and use of in China and global markets,” commented Xiaodong Wang, co-founder, director, and chairman of the Scientific Advisory Board of

John Oyler, co-founder, CEO and chairman of the Board of BeiGene, added, “It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing opportunity we envision in China and global markets. We believe the joint venture will provide a valuable asset for our long-term growth.”

Under the terms of the agreement, the cash contributions to consist of RMB 200 million ($30 million) from and a total of RMB 1 billion ($150 million) from GDD, including cash in equity investment of the JV company and a shareholder loan, which may be convertible into equity of the JV. For additional funding, the manufacturing factory subsidiary of the is expected to secure commercial loans of RMB 1 billion ($150 million).

is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the US, Australia and Taiwan, is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer.

RECOMMENDED FOR YOU

BeiGene & Guangzhou Development District to set up $ 330 mn biologics plant

JV will also provide funding for research and development of biologic drug candidates in China

JV will also provide funding for research and development of biologic drug candidates in China
Chinese biotechnology company Ltd and (GDD) have formed a joint venture, Co Ltd, that will invest RMB 2.2 billion ($ 330 million) to build a manufacturing facility in Guangzhou, Guangdong Province, China. The joint venture will also provide funding for research and development of biologic drug candidates in China.

“We are very pleased to announce our joint venture with the represent an important part of BeiGene’s overall R&D and manufacturing capabilities. This joint venture will enable to keep pace with a growing demand for the development and use of in China and global markets,” commented Xiaodong Wang, co-founder, director, and chairman of the Scientific Advisory Board of

John Oyler, co-founder, CEO and chairman of the Board of BeiGene, added, “It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing opportunity we envision in China and global markets. We believe the joint venture will provide a valuable asset for our long-term growth.”

Under the terms of the agreement, the cash contributions to consist of RMB 200 million ($30 million) from and a total of RMB 1 billion ($150 million) from GDD, including cash in equity investment of the JV company and a shareholder loan, which may be convertible into equity of the JV. For additional funding, the manufacturing factory subsidiary of the is expected to secure commercial loans of RMB 1 billion ($150 million).

is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the US, Australia and Taiwan, is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer.

image
Business Standard
177 22

BeiGene & Guangzhou Development District to set up $ 330 mn biologics plant

JV will also provide funding for research and development of biologic drug candidates in China

Chinese biotechnology company Ltd and (GDD) have formed a joint venture, Co Ltd, that will invest RMB 2.2 billion ($ 330 million) to build a manufacturing facility in Guangzhou, Guangdong Province, China. The joint venture will also provide funding for research and development of biologic drug candidates in China.

“We are very pleased to announce our joint venture with the represent an important part of BeiGene’s overall R&D and manufacturing capabilities. This joint venture will enable to keep pace with a growing demand for the development and use of in China and global markets,” commented Xiaodong Wang, co-founder, director, and chairman of the Scientific Advisory Board of

John Oyler, co-founder, CEO and chairman of the Board of BeiGene, added, “It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing opportunity we envision in China and global markets. We believe the joint venture will provide a valuable asset for our long-term growth.”

Under the terms of the agreement, the cash contributions to consist of RMB 200 million ($30 million) from and a total of RMB 1 billion ($150 million) from GDD, including cash in equity investment of the JV company and a shareholder loan, which may be convertible into equity of the JV. For additional funding, the manufacturing factory subsidiary of the is expected to secure commercial loans of RMB 1 billion ($150 million).

is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the US, Australia and Taiwan, is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer.

image
Business Standard
177 22